Diabetes and Vascular Disease

SAT-646 - Glycemic Outcomes in CGM-Naïve vs. Experienced Patients using Implantable CGM

Saturday, June 13, 2026

9:30 AM - 4:30 PM CT

Location: ENDOExpo; Poster Floor

Abstract Poster Presenter(s)

RT

Rishab Tandon, MD

Physician Resident
St. Francis-Emory Healthcare
Columbus, GA, United States

Senior Author/Primary Investigator(s)

RT

Rishab Tandon, MD

Physician Resident
St. Francis-Emory Healthcare
Columbus, GA, United States

Co-Author(s)

RT

Rishab Tandon, MD

Physician Resident
St. Francis-Emory Healthcare
Columbus, GA, United States
JT

Joan Torres Serrano, MD

Physician Resident, PGY-1
St. Francis-Emory Healthcare
Columbus, United States
BM

Brandi Muldrow, DO

Physician Resident, PGY-1
St. Francis-Emory Healthcare
Columbus, Georgia, United States
SN

Sehrish Noorali, MD

Physician Resident, PGY-1
St. Francis-Emory Healthcare
Columbus, Georgia, United States

Senior Author/Primary Investigator(s)

BB

Bantwal S. Baliga, MD

Director
East Alabama Endo, PC
Columbus, Georgia, United States

Co-Author(s)

BB

Bantwal S. Baliga, MD

Director
East Alabama Endo, PC
Columbus, Georgia, United States

Disclosure(s):

Rishab Tandon, MD: No financial relationships to disclose

Introduction &

Objective: The primary focus of this study is to compare the magnitude of HbA1c and GMI reduction in diabetic patients who are continuous glucose monitor (CGM)-naïve versus those transitioning from transcutaneous sensors. The study aims to determine the glycemic benefit of initiating an implantable CGM and whether transitioning to an implantable sensor provides superior clinical outcomes compared to traditional transcutaneous systems.

Methods: This single-center, 14-month study (Nov 2024-Dec 2025) analyzed n = 44 diabetic patients (mean age 67.16). Inclusion criteria required wear time > 75%, device duration > 3 months, and complete glycemic data. The cohort (mean wear time 93.8% ± 4.91%) included 38 patients on multiple daily injections and 27 on GLP-1 therapies. Paired t-tests assessed significance at 3 and 6 months.

Results: Baseline HbA1c for the entire cohort was 7.85% ± 1.94% (Naïve: 8.88% ± 2.83%; Prior transcutaneous: 7.51% ± 1.80%; Prior Eversense: 7.99% ± 0.91%; Prior dual-experienced with both transcutaneous and Eversense: 7.44% ± 1.59%). Total mean cohort Time in Range (TIR) was 78.11% ± 14.88%. Time spent 54-70 mg/dL was 1.23% ± 1.47%. Mean time below 54 mg/dL was 0.18% ± 0.28%. Post-initiation mean GMI at 2 weeks was 6.79% ± 0.49% (Naïve: 6.72% ± 0.25%; Prior transcutaneous: 6.78% ± 0.59%; Prior Eversense: 7.11% ± 0.44%; Dual: 6.62% ± 0.41%). At 3 months (n = 39), mean HbA1c reduction was 0.72% (p = 0.0068); naïve patients achieved 1.57% reduction and experienced patients achieved 0.53% (p = 0.0174). At 6 months (n = 27), mean reduction was 0.33% for the whole cohort.

Conclusion: Significant reductions in HbA1c and GMI indicate rapid stabilization upon initiating an implantable sensor. Naïve patients experienced a larger reduction. These outcomes exceed previously published results. Future analysis will calculate if implantable CGM usage results in fewer hospitalizations or ED visits compared to transcutaneous sensors or no CGM.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*